The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2011Multimodal MRI Markers for Parkinson's Disease
Objective/Rationale:
A measurement tool which accurately reflects not only motor deficits but also a host of cognitive dysfunctions seen frequently in Parkinson’s disease (PD) would improve diagnosis... -
Access to Data and Biospecimens, 2015BioFIND: Analysis of A-beta, Tau and P-tau in CSF Samples
Study Rationale: Mixed pathology is common in all neurodegenerative diseases including Parkinson’s disease (PD). Three cerebrospinal fluid (CSF) biomarkers, Ab1-42, t-tau and p-tau181, provide an...
-
Therapeutic Pipeline Program, 2014Evaluating the Safety, Tolerability and Efficacy of SYN120 in Parkinson’s Disease Dementia
Study Rationale:
Cognitive impairments — common in Parkinson’s disease — are associated with an imbalance in neurotransmitters (substances that allow nerve cells to communicate with one another) such... -
GBA Biology and Therapies, 2018Molecular Imaging and Computer Typing in GBA-PD and Asymptomatic GBA-mutation Carriers
Study Rationale:
People who have a mutation in the GBA gene have a higher risk of developing Parkinson’s disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia... -
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023SUPPLEMENT | CMA as a Means to Counteract Alpha-synuclein Pathology in Non-human Primates”
Study Rationale: One of the main pathways to remove excess amounts of the alpha-synuclein protein that is linked to Parkinson’s disease (PD) is the lysosomal chaperone-mediated autophagy (CMA) pathway...
-
Therapeutics Development Initiative, 2011Dopamine D1 Positive Modulators for the Treatment of Parkinson's Disease
Objective/Rationale:
L-DOPA is the standard treatment of Parkinson’s disease (PD) but prolonged use results in dyskinesia. D2 agonists often require L-DOPA supplementation and can cause side effects...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.